My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by AstraZeneca

< Previous 1 2 3 4 5 6 7 8 9 Next >
AIRSUPRA® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol
From AstraZeneca
Via Business Wire
Tickers AZN
SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis
From AstraZeneca
Via Business Wire
Tickers AZN
TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer
From AstraZeneca
Via Business Wire
Tickers AZN
Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III ​trial
From AstraZeneca
Via Business Wire
Tickers AZN
FLUMIST (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery
From AstraZeneca
Via Business Wire
Tickers AZN
AstraZeneca results: H1 and Q2 2025
From AstraZeneca
Via Business Wire
Tickers AZN
IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and gastroesophageal junction cancers
From AstraZeneca
Via Business Wire
Tickers AZN
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
From AstraZeneca
Via Business Wire
Tickers AZN
TAGRISSO® (osimertinib) plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer
From AstraZeneca
Via Business Wire
Tickers AZN
Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension
From AstraZeneca
Via Business Wire
Tickers AZN
DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
From AstraZeneca
Via Business Wire
Tickers AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer
From AstraZeneca
Via Business Wire
Tickers AZN
Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma
From AstraZeneca
Via Business Wire
Tickers AZN
AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025
From AstraZeneca
Via Business Wire
Tickers AZN
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11
From AstraZeneca
Via Business Wire
Tickers AZN
BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma
From AstraZeneca
Via Business Wire
Tickers AZN
AstraZeneca's Q1 2025 Financial Results
From AstraZeneca
Via Business Wire
Tickers AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer
From AstraZeneca
Via Business Wire
Tickers AZN
​​AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
From AstraZeneca
Via Business Wire
Tickers AZN
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
From AstraZeneca
Via Business Wire
Tickers AZN
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
From AstraZeneca
Via Business Wire
Tickers AZN
AstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer
From AstraZeneca
Via Business Wire
Tickers AZN
IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers
From AstraZeneca
Via Business Wire
Tickers AZN
Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps
From AstraZeneca
Via Business Wire
Tickers AZN
Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.